"We Envision Growth Strategies Most Suited
to Your Business"
The global multiple sclerosis drugs market size is projected to reach USD 40.66 billion by 2027 owing to increased funding for medical research in emerging economies, shares Fortune Business Insights™ in its report, titled “Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2020-2027”. According to the report, the market value was at USD 25.00 billion in 2019 and is expected to register a CAGR of 7.1% from 2020 to 2027.
The multiple sclerosis drugs market growth is likely to be hindered throughout 2020 as medical experts are advising MS patients to avoid taking disease-modifying therapies (DMT) for their condition because these therapies increase the patients’ vulnerability to the coronavirus. However, with patients delaying their hospital visits, the sales of MS drugs has spiked in the past few months.
Adamas Releases Update on Its INROADS Study
In June 2020, Adamas Pharmaceuticals, the California-based specialist in neurological diseases, completed its evaluation of the efficacy of its ADS-5102 medication designed for multiple sclerosis patients with walking impairment. The evaluation was done through a 12-week-long, randomized, and placebo-controlled study called INROADS. According to the study results released by the company, MS patients taking a 274gm dose of ADS-5102 displayed an improvement rate of 21.1% compared to 11.3% of those on placebo. The company now plans on conducting a Phase 3 confirmatory study, as per the directives of the US Food and Drug Administration (FDA), before it is made commercially available in the market.
To get a detailed report summary and research scope of this market, click here:
Issuance of Comprehensive Guidelines for MS Treatment to Augment Market Growth
Multiple sclerosis is a complex disease and needs to be treated with utmost care and accuracy. To enable neurologists and other physicians to efficiently manage MS patients, organizations such as the European Academy of Neurology (EAN) and the American Academy of Neurology (AAN) have been issuing guidelines on treating MS patients. For example, the AAN recommends the use of alemtuzumab, fingolimod, or natalizumab for active relapsing remitting MS (RRMS) patients. In case of patients with primary progressive MS (PPMS), both the AAN and the EAN advise neurologists to opt for ocrelizumab. The two organizations also come out with specific guidelines for the use of MRI in treating MS patients. These and many other guidelines framed by expert bodies such as the EAN and the AAN are augmenting the MS treatment market growth.
Intense Focus of Players on Clinical Trials to Intensify Market Competition
Pharmaceutical giants such as Biogen and Pfizer are dominating the competitive landscape of this market on account of their diverse product portfolios and massive global presence. The focus of these companies has always been on conducting clinical trials, with strong support from intensive R&D activities. As a result, these companies are constantly developing novel drugs and therapies for different health conditions, thereby tightening their hold on the pharmaceuticals market.
List of Key Companies Profiled in this Market Report:
Further Report Findings:
Table of Segmentation:
Value (USD billion)
By Drug Class
By Route of Administration
By Distribution Channel